The Middle East & Africa breast cancer therapeutics market was valued at US$ 762.61 million in 2022 and is expected to reach US$ 1,342.86 million by 2030; it is estimated to grow at a CAGR of 7.3% from 2022 to 2030.
Growing Burden of Breast Cancer Fuels the Middle East & Africa Breast Cancer Therapeutics Market
Breast cancer is considered the most common cancer among women worldwide, and its incidence is increasing globally. Factors such as lifestyle changes, hormonal imbalances, genetic predisposition, and environmental factors contribute to the rising prevalence of breast cancer. According to WHO, in 2020, 685,000 people died worldwide from breast cancer, accounting for 2.3 million new diagnoses. Breast cancer is one of the most common cancers globally, with 7.8 million women alive as of the end of 2020 who had received a diagnosis within the previous five years. All across the world, breast cancer affects women at any age after adolescence. However, its prevalence rises with age. With the rise in breast cancer cases, there is an increasing need for effective and targeted therapies to improve patient outcomes. This has led to a surge in research and development activities in breast cancer therapeutics. Therefore, the growing burden of breast cancer drives the Middle East & Africa breast cancer therapeutics market.
Middle East & Africa Breast Cancer Therapeutics Market Overview
The breast cancer therapeutics market in the Middle East & Africa is segmented into UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. Changing healthcare infrastructure and public-private partnerships between government and international players are strengthening the healthcare sector in the country. These partnerships and privatization efforts align with the policies included in the "Vision 2030" strategy by the Saudi government to transform the national economy. As per the International Trade Administration, the Saudi Arabian government invested about US$ 65 billion to build the country's healthcare infrastructure as part of Vision 2030. In addition, it intends to increase private sector contribution from 40% to 65% by 2030, with a focus on the privatization of 290 hospitals and 2,300 primary health centers. Increased investment in infrastructure and innovation is anticipated to encourage growth in the market.
In June 2023, MSD GCC expanded its oncology research partnership with The Department of Health Abu Dhabi (DoH). The deal, signed at the BIO International Convention 2023, signified the continuation of a long-term collaboration between the two entities. Within the framework of their renewed partnership, the two parties will collaborate to initiate two observational research studies in the field of oncology, focusing on non-small cell lung cancer and triple-negative breast cancer. The studies aim to advance the ability to address the healthcare challenges associated with these diseases and improve patient outcomes. Therefore, the growing efforts of the companies to spread awareness and development of new and innovative products in the country significantly contribute to the growth of the breast cancer therapeutics market in the UAE.
In October 2021, the National Bank of Kuwait (NBK) launched an annual campaign to promote women's health during breast cancer awareness month. The campaign is part of the Banks ongoing campaign to raise social awareness regarding breast cancer and promote its ways of prevention. Therefore, the above-mentioned factors significantly fuel the breast cancer therapeutics market growth.
Middle East & Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Breast Cancer Therapeutics Market Segmentation
The Middle East & Africa breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.
Based on drug therapy, the Middle East & Africa breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the Middle East & Africa breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.
By distribution channel, the Middle East & Africa breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.
Based on country, the Middle East & Africa breast cancer therapeutics market is categorized into South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa breast cancer therapeutics market in 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the Middle East & Africa breast cancer therapeutics market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 762.61 Million |
| Market Size by 2030 | US$ 1,342.86 Million |
| CAGR (2022 - 2030) | 7.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Drug Therapy
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc
The Middle East & Africa Breast Cancer Therapeutics Market is valued at US$ 762.61 Million in 2022, it is projected to reach US$ 1,342.86 Million by 2030.
As per our report Middle East & Africa Breast Cancer Therapeutics Market, the market size is valued at US$ 762.61 Million in 2022, projecting it to reach US$ 1,342.86 Million by 2030. This translates to a CAGR of approximately 7.3% during the forecast period.
The Middle East & Africa Breast Cancer Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Breast Cancer Therapeutics Market report:
The Middle East & Africa Breast Cancer Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Breast Cancer Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Breast Cancer Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Breast Cancer Therapeutics Market
